Benserazide - Pharmacology
Research News and Information

Monday, November 23, 2009

L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study.

Jun 2009 Functional connectivity (FC) analyses of resting-state fMRI data allow for the mapping of large-scale functional networks, and provide a novel means of examining the impact of dopaminergic challenge. Here, using a double-blind, placebo-controlled ... Read more...

Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).

30 May 2009 OBJECTIVES: To investigate the pharmacokinetics of talipexole hydrochloride tablets and the potential influence of Madopar (benserazide and levodopa combination; co-beneldopa) tablets on talipexole's pharmacokinetics when the two tablets are ... Read more...

Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

20 Jan 2009 RATIONALE: Dyskinesia affects the majority of levodopa-treated parkinsonian patients within 5-10 years of treatment with levodopa. Clinical and preclinical observations suggest that an increase in serotoninergic transmission can contribute to the ... Read more...

Latest indexed articles for 'Benserazide - Pharmacology'

These are the very latest articles for this heading:

• L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study. Jun 2009
• Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa). 30 May 2009
• Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. 20 Jan 2009
• Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. 25 Oct 2008
• Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease. 28 Jul 2008
• Molecular analyses of GCH-1, TH and parkin genes in Chinese dopa-responsive dystonia families. 9 Jun 2008
• Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum. 29 Apr 2008
• Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson's disease. 6 Jun 2007
• The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. 11 May 2007
• Delayed L-DOPA-induced hyperalgesia. 2 Dec 2006
• Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications. 15 Nov 2006
• The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers. 17 Oct 2006
• Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice. 30 Jul 2006
• Effect of L-dopa decarboxylase inhibitor benserazide on renal function in streptozotocin-diabetic rats. 18 Apr 2006
• L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase. 26 Feb 2006
• Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa. 13 Aug 2005
• Cholinopositive effect of dilept (neurotensin peptidomimetic) as the basis of its mnemotropic effect. 27 Feb 2005
• L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. 29 Aug 2004
• Influence of dipeptidyl peptidase inhibitors on growth, peptidase activity, and ammonia production by ruminal microorganisms. 30 Jul 2004
• Antinociceptive mechanism of L-DOPA. 29 Jun 2004

See a longer list of these articles.

Technical information about 'Benserazide'

Definition: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.

Chemical name: DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide

Registry Number: 322-35-0

Descriptor UI: D001545

Alternative terms: Benserazide; Seryltrihydroxybenzylhydrazine; Seryltrihydroxy Benzylhydrazine; Benzylhydrazine, Seryltrihydroxy; DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; Serazide; Ro 4-4602; Ro 4 4602; Ro 44602;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antiparkinson Agents; Enzyme Inhibitors; Dopamine Agents;

Tree Number: D02.442.175;

Online Note: use BENSERAZIDE to search SERYLTRIHYDROXY BENZYLHYDRAZINE 1973-78 (as Prov 73-74)

History Note: 91(79); was see under HYDRAZINES 1979-90; was SERYLTRIHYDROXY BENZYLHYDRAZINE see under HYDRAZINES 1973-78 (Prov 1973-74)